DeepMed Research

Boryung Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase IV Clinical Study to Compared the Efficacy and Safety of Switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes

Phase 4

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Metformin
Drug: Dapagliflozin/Pioglitazone
Drug: Dapagliflozin/Sitagliptin

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 204

Registration Number: NCT06972732

Locations: 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: BR3006
Drug: BR3006A
Drug: BR3006B
Drug: BR3006C

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 40

Registration Number: NCT06890299

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: BR3006
Drug: BR3006A
Drug: BR3006B
Drug: BR3006C

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 53

Registration Number: NCT06890286

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1018 and Coadministration of BR1018A and BR1018B in Healthy Adult Volunteers

Phase 1

Not yet recruiting

Conditions: Essential Hypertension
Primary Hypercholesterolemia

Interventions: Drug: BR1018
Drug: BR1018A
Drug: BR1018B

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 60

Registration Number: NCT06889012

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: BR1400-1
Drug: BR1400-2
Drug: BR1400-3

First Posted Date: 2025-03-21

Last Posted Date: 2025-03-21

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 28

Registration Number: NCT06889064

Locations: 🇰🇷
Seoul Bumin Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: BR3409
Drug: BR3409-1
Drug: BR3409-2

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 50

Registration Number: NCT06879158

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: BR3409
Drug: BR3409-1
Drug: BR3409-2

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-17

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 40

Registration Number: NCT06879132

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

Phase 1

Recruiting

Conditions: Metastatic Adenocarcinoma of the Pancreas

Interventions: Drug: BR2021
Drug: BR2021-1

First Posted Date: 2025-03-10

Last Posted Date: 2025-04-10

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 20

Registration Number: NCT06867497

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of

A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

Phase 2

Recruiting

Conditions: Schizophrenia

Interventions: Drug: BR5402A
Drug: BR5402A-1
Drug: BR5402B
Drug: BR5402B-1
Drug: BR5402C
Drug: BR5402C-1
Drug: BR5402D
Drug: BR5402D-1

First Posted Date: 2025-02-12

Last Posted Date: 2025-02-12

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 120

Registration Number: NCT06821945

Locations: 🇰🇷
Hanyang University Guri Hospital, Guri-si, Korea, Republic of
🇰🇷
Kyungbook National university hospital, Daegu, Korea, Republic of

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions

Phase 1

Completed

Conditions: Essential Hypertension

Interventions: Drug: BR1015
Drug: BR1015-2
Drug: BR1015-3

First Posted Date: 2024-12-20

Last Posted Date: 2025-04-09

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 60

Registration Number: NCT06744426

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy